Granules India Ltd. logo

Granules India Ltd. (GRANULES)

Market Closed
7 Aug, 22:00
MSE MSE
872. 45
+34.25
+4.0861%
- Market Cap
- P/E Ratio
6% Div Yield
25,485 Volume
- Eps
838.2
Previous Close
Add Transaction
Day Range
835.5 882.05
Year Range
434.5 910
Want to track GRANULES and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

GRANULES closed Friday higher at ₹872.45, an increase of 4.0861% from Thursday's close, completing a monthly increase of 7.0294% or ₹57.3. Over the past 12 months, GRANULES stock gained 44.9493%.
GRANULES pays dividends to its shareholders, with the most recent payment made on Sep 06, 2025. The next announced payment will be in In 3 weeks on Sep 05, 2026 for a total of ₹1.75.
The last earnings report, released on May 20, 2026, missed the consensus estimates by -7%. On average, the company has fell short of earnings expectations by -2.06%, based on the last three reports.
Granules India Ltd. has completed 1 stock splits, with the recent split occurring on Mar 23, 2015.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on XNSE (INR).

GRANULES Chart

Granules India Ltd. (GRANULES) FAQ

What is the stock price today?

The current price is ₹872.45.

On which exchange is it traded?

Granules India Ltd. is listed on MSE.

What is its stock symbol?

The ticker symbol is GRANULES.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 6%.

What is its market cap?

As of today, no market cap data is available.

Has Granules India Ltd. ever had a stock split?

Granules India Ltd. had 1 splits and the recent split was on Mar 23, 2015.

Granules India Ltd. Profile

Specialty Retail Industry
Consumer Discretionary Sector
Dr. Kandiraju Venkata Sita Ram Rao B.Tech, M.E., Ph.D. CEO
MSE Exchange
INE101D01020 ISIN
India Country
4,057 Employees
30 Jul 2026 Last Dividend
23 Mar 2015 Last Split
- IPO Date

Overview

Granules India Limited is a prominent company specializing in the pharmaceutical sector, with a focus on manufacturing and selling a broad array of products, including active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs). Established in 1984, the company prides itself on its strong presence both within India and on the international stage. Its headquarters are located in Hyderabad, India, positioning it strategically in one of the country's major hubs for the pharmaceutical industry. Granules India Limited caters to a diverse set of therapeutic categories, leveraging its extensive experience and innovation capabilities to address the dynamic needs of the healthcare sector.

Products and Services

  • Active Pharmaceutical Ingredients (APIs):

    Granules India Limited produces APIs for a variety of therapeutic uses, including anti-retrovirals, anti-hypertensives, anti-histamines, anti-infectives, analgesics, anti-coagulants, anti-fibriotics, and platelet inhibitors. These ingredients are essential for the pharmaceutical industry, serving as the active components in medications that treat a wide range of diseases and conditions.

  • Pharmaceutical Formulation Intermediates:

    The company also specializes in the production of intermediates that are key in the formulation of pharmaceuticals. These intermediates are crucial steps in the drug manufacturing process, ultimately leading to the production of effective and safe medications.

  • Finished Dosages (FDs):

    Granules India offers a wide array of finished dosage forms, including tablets, caplets, and press-fit capsules. These are available in various packaging options such as bulk, blister packs, and bottles. The company's capability to deliver high-quality finished products makes it a vital player in the global pharmaceutical market.

  • High Potent Products:

    In addition to its range of APIs and FDs, Granules India Limited has capabilities in manufacturing high potent products. These products require specialized handling and manufacturing processes due to their potency and are critical for treating certain health conditions.

  • Oncology Products:

    The company also offers products for oncology, addressing the growing global need for effective cancer treatments. This includes the development and manufacturing of drugs designed to meet the specific requirements of oncology patients, showcasing Granules India Limited's commitment to contributing to the fight against cancer.

Contact Information

Address: My Home Hub
Phone: 91 40 6904 3500